Molecular Diagnostics is Growing as Drug Discovery Technologies Evolve

Author：

ISSN： 1537-1336

Source： Diagnostic Innovation, Vol.11, Iss.4, 2002-01, pp. : 2-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

As technology platforms evolve to meet today's research needs, it is becoming more obvious that they are also concurrently making possible diagnostic testing on a level of complexity that was unthinkable a decade ago. Mass sequencing of the entire genome, as performed by the Human Genome Project, has identified a number of genes now believed to be associated with common diseases, such as asthma, obesity, type 2 diabetes and osteoporosis, among many others. The pharmaceutical industry has begun to recognize and embrace the vast opportunities that human genomic information can offer for the discovery of therapeutic targets and pharmacogenomics. Much of this research will spill over into discovery of new diagnostic targets as well. In fact, many of the same targets that are used during the drug discovery process will ultimately be useful in diagnosing disease, predicting which therapies are most likely to benefit the patient, or in monitoring response to therapy.